Gilead’s Kite Signs US$3.15 B Genome Editing Deal with Sangamo
By Heather Cartwright
Pharma Deals Review: Vol 2018 Issue 3 (Table of Contents)
Published: 14 Mar-2018
DOI: 10.3833/pdr.v2018.i3.2310 ISSN: 1756-7874
Section: Technology Access
Fulltext:
Abstract
In a major endorsement of Sangamo Therapeutics’ zinc finger nuclease (ZFN) genome editing technology, Gilead Sciences’ Kite Pharma has secured an exclusive licence to use the platform for the development of next-generation ex vivo cellular immunotherapies in oncology for both autologous and allogeneic use...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
Login Problems
RSS